Ir para o conteúdo principal

Pulmatrix (NASDAQ: PULM) — Perfil da empresa, notícias e dados financeiros

Logo de Pulmatrix
PULM Pulmatrix
Pulmatrix primary media
Perfil da empresa

Pulmatrix

Pulmatrix (NASDAQ:PULM) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of pulmonary diseases. With a keen interest in leveraging its proprietary technology platform, Pulmatrix aims to improve the lives of patients suffering from serious pulmonary conditions including chronic obstructive pulmonary disease (COPD), asthma, and infectious diseases by developing inhaled therapies that lead to better efficacy, safety, and convenience. One of the company's flagship projects involves a novel formulation designed to effectively deliver medications directly to the lungs, promising a significant advancement in the treatment of pulmonary diseases. Pulmatrix is motivated by its mission to address the unmet medical needs within the respiratory health sector, pushing the boundaries of pulmonary medicine through cutting-edge research and development.

Resumo

Public USParticipação acionária
2003Ano de fundação
23Funcionários
Bedford, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Pulmatrix

  • PUR1900, an inhaled antifungal medication aimed at treating allergic bronchopulmonary aspergillosis in asthma patients.
  • PUR3100, a fast-acting, inhalable migraine therapy designed for rapid relief.
  • iSPERSE technology, a proprietary dry powder platform for delivering small molecule drugs directly to the lungs.
  • PUR5700, a novel inhaled formulation targeting the treatment of idiopathic pulmonary fibrosis, aiming to reduce fibrosis progression.

equipe executiva do Pulmatrix

  • Peter LudlumInterim CEO & Interim CFO
  • Alexander M. KlibanovFounder

Principais indicadores financeiros

Resultados divulgados pela Pulmatrix, em USD.

Cap. de mercado
5,5 mi
Receita (TTM)
3 mil
P/L
—
LPA (diluído, TTM)
-1.1
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Pulmatrix
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-5,2 mi-5,2 mi
7,8 mi-9,8 mi-9,6 mi
7,3 mi-14,7 mi-14,1 mi
6,1 mi-18,9 mi-18,7 mi